Tocqueville Asset Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,925
Closed -$293K 559
2025
Q2
$293K Hold
3,925
﹤0.01% 477
2025
Q1
$249K Hold
3,925
﹤0.01% 477
2024
Q4
$306K Hold
3,925
﹤0.01% 482
2024
Q3
$315K Hold
3,925
0.01% 456
2024
Q2
$325K Hold
3,925
0.01% 448
2024
Q1
$335K Hold
3,925
0.01% 444
2023
Q4
$336K Sell
3,925
-341
-8% -$29.5K 0.01% 440
2023
Q3
$382K Sell
4,266
-480
-10% -$42.9K 0.01% 422
2023
Q2
$404K Sell
4,746
-12,681
-73% -$1.07M 0.01% 430
2023
Q1
$1.44M Sell
17,427
-6,218
-26% -$503K 0.03% 303
2022
Q4
$1.86M Sell
23,645
-1,435
-6% -$115K 0.04% 288
2022
Q3
$1.86M Sell
25,080
-154,750
-86% -$11.1M 0.04% 286
2022
Q2
$11.7M Hold
179,830
0.21% 113
2022
Q1
$11.4M Sell
179,830
-55,039
-23% -$2.99M 0.17% 132
2021
Q4
$12.5M Buy
234,869
+53,283
+29% +$3.25M 0.17% 134
2021
Q3
$12.8M Sell
181,586
-6,016
-3% -$380K 0.19% 129
2021
Q2
$12.5M Buy
187,602
+163,750
+687% +$11.6M 0.18% 132
2021
Q1
$2.65M Sell
23,852
-1,212
-5% -$150K 0.04% 336
2020
Q4
$2.98M Sell
25,064
-119
-0.5% -$12.8K 0.05% 297
2020
Q3
$2.2M Buy
25,183
+10,985
+77% +$960K 0.04% 298
2020
Q2
$1.27M Buy
+14,198
New +$1.43M 0.03% 359
2019
Q3
Sell
-4,083
Closed -$491K 764
2019
Q2
$491K Sell
4,083
-529
-11% -$52K 0.01% 603
2019
Q1
$403K Sell
4,612
-209
-4% -$19K 0.01% 627
2018
Q4
$482K Buy
4,821
+247
+5% +$25.9K 0.01% 565
2018
Q3
$524K Buy
+4,574
New +$474K 0.01% 609
2015
Q4
Sell
-269,502
Closed -$8.71M 933
2015
Q3
$8.71M Buy
269,502
+2,935
+1% +$110K 0.12% 212
2015
Q2
$11M Buy
266,567
+22,802
+9% +$961K 0.13% 198
2015
Q1
$10.9M Buy
243,765
+163,739
+205% +$6.84M 0.13% 193
2014
Q4
$3M Buy
80,026
+18,281
+30% +$670K 0.03% 405
2014
Q3
$2.16M Sell
61,745
-325
-0.5% -$11.6K 0.02% 421
2014
Q2
$2.19M Buy
+62,070
New +$2.07M 0.02% 465

Other funds holding HAE

Tocqueville Asset Management's HAE Position: Q3 2025 in Review

Tocqueville Asset Management sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 3,925 shares — an estimated $293K sold.

Tocqueville Asset Management first reported a position in HAE in Q2 2014 and held it in 31 quarters. The position peaked at $12.8M in Q3 2021. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • Tocqueville Asset Management reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
  • Tocqueville Asset Management sold 3,925 Haemonetics shares in Q3 2025, an estimated $293K.
  • Tocqueville Asset Management first reported a position in Haemonetics in Q2 2014 and held it in 31 quarters.
  • Tocqueville Asset Management's Haemonetics position peaked at $12.8M in Q3 2021.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on Tocqueville Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.